Leerink Swann initiated coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report issued on Monday morning, MarketBeat.com reports. The firm issued an underperform rating and a $28.00 target price on the stock.

DCPH has been the subject of several other research reports. JPMorgan Chase & Co. lifted their price objective on shares of Deciphera Pharmaceuticals from $30.00 to $33.00 and gave the company an overweight rating in a research note on Monday, June 4th. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, June 4th. Piper Jaffray Companies lifted their price objective on shares of Deciphera Pharmaceuticals to $50.00 and gave the company an overweight rating in a research note on Tuesday, June 12th. Raymond James initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 29th. They issued an outperform rating and a $47.00 price objective for the company. Finally, SunTrust Banks initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, July 5th. They issued a buy rating for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $48.09.

Deciphera Pharmaceuticals stock opened at $38.50 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 18.44 and a quick ratio of 18.44. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $45.61. The company has a market cap of $1.50 billion and a price-to-earnings ratio of -12.91.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.03. analysts forecast that Deciphera Pharmaceuticals will post -2.59 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in DCPH. Redmile Group LLC increased its stake in shares of Deciphera Pharmaceuticals by 79.9% in the 2nd quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock valued at $58,123,000 after acquiring an additional 655,800 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Deciphera Pharmaceuticals in the 2nd quarter valued at $21,989,000. Orbimed Advisors LLC increased its stake in shares of Deciphera Pharmaceuticals by 30.8% in the 2nd quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock valued at $78,924,000 after acquiring an additional 472,800 shares in the last quarter. Opaleye Management Inc. acquired a new stake in Deciphera Pharmaceuticals in the 1st quarter valued at $7,314,000. Finally, FMR LLC grew its position in Deciphera Pharmaceuticals by 33.5% in the 2nd quarter. FMR LLC now owns 1,182,091 shares of the company’s stock valued at $46,515,000 after purchasing an additional 296,571 shares during the period. Institutional investors own 53.53% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Read More: Closed-End Mutual Funds

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.